Effect of an .ALPHA.-glucosidase inhibitor, voglibose, in diabetic patients combined with liver cirrhosis.
|
Accession number;99A0540499
|
| Title;Effect of an .ALPHA.-glucosidase inhibitor, voglibose, in diabetic patients combined with liver cirrhosis. |
| Author;
YOSHITSUGU M
(Japanese Red Cross Medical Center)
HIYOSHI T
(Japanese Red Cross Medical Center)
AKASU F
(Japanese Red Cross Medical Center)
|
Journal Title;Medical Consultation & New Remedies
|
Journal Code:Z0942A
|
ISSN:0037-380X
|
|
VOL.36;NO.3;PAGE.218-222(1999)
|
| Figure&Table&Reference;FIG.6, TBL.1, REF.12 |
| Pub. Country;Japan |
| Language;English |
| Abstract;In patients with liver cirrhosis, there is often a postprandial hyperglycemia. The effect of an .ALPHA.-glucosidase inhibitor (voglibose) on blood glucose levels and liver function tests was evaluated in 12 diabetic patients combined with liver cirrhosis. The patients received voglibose (0.6mg a day) orally immediately before each meal for 4 weeks. This agent significantly reduced postprandial blood glucose levels. Fasting serum total cholesterol and triglyceride levels which were lower in pretreatment period tended to increase during 4-week treatment period, but the differences were not significant, whereas fasting serum HDL cholesterol levels were unaffected. Fasting serum AST, ALT, .GAMMA.-GTP, ChE activities and albumin levels tended to improve after voglibose treatment, and fasting blood ammonia levels were significantly decreased after the treatment. This agent did not cause any side effects except for 2 cases who showed mild hypoglycemic attacks at the early stage of the treatment period. This results suggest that an .ALPHA.-glucosidase inhibitor, voglibose has a beneficial effect on postprandial hyperglycemia and liver function tests in diabetic patients combined with liver cirrhosis. (author abst.) |
|
|
|
Related Articles;
|
|
